Publications and Presentations

Combination immunotherapy anti-PD-1 antibody with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET

Combination immunotherapy anti-PD-1 antibody with CBT-101 (c-MET inhibitor)  demonstrates enhanced activity in tumors not dependent on c-MET